Submit Content
Get the latest delivered to your inbox
Privacy Policy

Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

    The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award Image

    POSTED 

    05-17-21

    The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award

    Alkermes plc is a recipient of The Boston Club’s first President’s Award, recognizing organizations that are leaders in supporting the advancement of women in the C-suite and boardroom.
    Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer Image

    POSTED 

    05-13-21

    Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

    Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants® program beginning on May 20, 2021.
    Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month Image

    POSTED 

    05-04-21

    Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month

     Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May. The meetings, all held virtually, include:
    Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic Image

    POSTED 

    11-04-20

    Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic

    As the use of telehealth services has expanded during the COVID-19 pandemic, results from a survey conducted by The Harris Poll showed that more than one in four (27%) U.S. adults surveyed were currently using telepsychiatry (“telepsych”) services for mental health care.
    Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience Image

    POSTED 

    09-15-20

    Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

    Alkermes plc (Nasdaq: ALKS) recently announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
    Alkermes Releases Third Annual Corporate Responsibility Report Image

    POSTED 

    07-29-20

    Alkermes Releases Third Annual Corporate Responsibility Report

    Alkermes plc (Nasdaq: ALKS) today released its third annual Corporate Responsibility Report.  The report highlights the company’s corporate and social responsibility and environmental sustainability efforts, including recognition of the importance of continuing to increase the sophistication of moni...
    Alkermes Announces 3rd Annual ALKERMES PATHWAYS RESEARCH AWARDS℠  Program and 2019 Recipients Image

    POSTED 

    06-29-20

    Alkermes Announces 3rd Annual ALKERMES PATHWAYS RESEARCH AWARDS℠  Program and 2019 Recipients

    Alkermes plc (Nasdaq: ALKS) today announced that applications are now being accepted for the annual ALKERMES PATHWAYS RESEARCH AWARDSSM. The competitive grants program is designed to support the next generation of researchers working on the front lines to advance understanding and awareness of centr...
    Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities Image

    POSTED 

    06-24-20

    Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities

    Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special edition of the company's signature Alkermes Inspiration Grants® program, that was established to assist nonprofit organizations in their work to rap...
    Collaborative and Risk-focused Engagement (CaRE™) at Alkermes Image

    POSTED 

    05-07-20

    Collaborative and Risk-focused Engagement (CaRE™) at Alkermes

    In 2018, we significantly enhanced CaRE™, our proprietary risk mitigation program designed to encourage employees to preemptively identify and address EHSS risks and enhance sustainability.
    Alkermes logo

    Alkermes

    Alkermes

    Join today and get the latest delivered to your inbox